(±)-LY 395756

Discontinued Product

3272 has been discontinued.

View all Glutamate (Metabotropic) Group II Receptors products.
Description: Mixed mGlu2 agonist/ mGlu3 antagonist
Chemical Name: (1S,2S,4R,5R,6S)-rel-2-Amino-4-methylbicyclo[3.1.0]hexane-2,6-dicarboxylic acid
Purity: ≥98% (HPLC)
Datasheet
Citations (2)
Reviews
Literature (4)

Biological Activity for (±)-LY 395756

(±)-LY 395756 is a selective metabotropic glutamate ligand for mGlu2 and mGlu3 receptors (Ki values are 0.165 μM and 0.302 μM respectively). Acts as an agonist at mGlu2 and antagonist at mGlu3. Analog of LY 354740 (Cat. No. 3246).

Technical Data for (±)-LY 395756

M. Wt 199.21
Formula C9H13NO4
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 852679-66-4
PubChem ID 11310142
InChI Key BQVZICWQBFTOJX-QNDZYWSYSA-N
Smiles N[C@]1([C@](O)=O)[C@@]2([H])[C@@]([C@@H]2[C@](O)=O)([H])[C@H](C)C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for (±)-LY 395756

Certificate of Analysis / Product Datasheet
Select another batch:

References for (±)-LY 395756

References are publications that support the biological activity of the product.

Dominguez et al (2005) Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist. J.Med.Chem. 48 3605 PMID: 15887967

View Related Products by Product Action

View all Glutamate (Metabotropic) Group II Receptor Agonists

Keywords: (±)-LY 395756, (±)-LY 395756 supplier, LY395756, agonist, metabotropic, glutamate, ligand, receptor, receptors, mGlu2, mGlu3, Glutamate, (Metabotropic), Group, II, Receptors, 3272, Tocris Bioscience

2 Citations for (±)-LY 395756

Citations are publications that use Tocris products. Selected citations for (±)-LY 395756 include:

Wang et al (2013) Group II metabotropic glutamate receptor agonist LY379268 regulates AMPA receptor trafficking in prefrontal cortical neurons. Mol Pain 8 e61787 PMID: 23593498

Johnson (2017) Metabotropic glutamate receptor 2 inhibits thalamically-driven glutamate and DA release in the dorsal striatum. Neuropharmacology 117 114 PMID: 28159646


Reviews for (±)-LY 395756

There are currently no reviews for this product. Be the first to review (±)-LY 395756 and earn rewards!

Have you used (±)-LY 395756?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.